Loss of p16 protein expression associated with methylation of the p16(INK4A) gene is a frequent finding in Hodgkin's disease

Laboratory Investigation

Volumn 79, Issue 12, 1999, Pages 1453-1459

  García, Juan F ^a   Villuendas, Raquel ^a   Algara, Patrocinio ^a   Sáez, Ana I ^a   Sánchez Verde, Lidia ^a   Martínez Montero, Juan C ^a   Martínez, Pedro ^a   Piris, Miguel A ^a  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D; PROTEIN P16;

ARTICLE; CELL CYCLE G2 PHASE; CHROMOSOME LOSS; ENZYME INHIBITION; GENE FREQUENCY; GENE INACTIVATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; METHYLATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; GENES, P16; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 0033391985     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D, and Sidransky D (1995). Frequency of homozygous deletion at p16/CDKN2 in primary tumors. Nat Genet 11:210-212.
2. Cayuela JM, Madani A, Sanhes L, Stern MH, and Sigaux F (1996). Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. Blood 87:2180-2186.
3. Chen WG, Chen YY, Kamel OW, Koo CH, and Weiss LM (1996). p53 mutations in Hodgkin's disease. Lab Invest 75:519-527.
4. Cohen JA and Geradts J (1997). Loss of Rb and MTS1/CDKN2 (p16) expression in human sarcomas. Hum Pathol 28:893-898.
5. Dreyling MH, Bohlander SK, Le Beau MM, and Olopade Ol (1995). Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies. Blood 86: 1931-1938.
6. Elenitoba-Johnson KS, Gascoyne RD, Lim MS, Chanabai M, Jaffe ES, and Raffeld M (1998). Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 91:4677-4685.
7. Geradts J, Andriko JW, and Abbondanzo SL (1998). Loss of tumor suppressor gene expression in high-grade but not low-grade non-Hodgkin's lymphomas. Am J Clin Pathol 109:669-674.
8. Geradts J, Kratzke RA, Niehans GA, and Lincoln CE (1995). Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: Correlation with retinoblastoma protein expression. Cancer Res 55:6006-6011.
9. Gerdes J, Van Baarlen J, Pileri S, Schwarting R, Van Unnik JAM, and Stein H (1987). Tumor cell growth fraction in Hodgkin's disease. Am J Pathol 128:390-393.
10. Gombart AF, Morosetti R, Miller CW, Said JW, and Koeffler HP (1995). Deletions of the cyclin-dependent kinase inhibitor genes p16INK4A and p15INK4B in non-Hodgkin's lymphomas. Blood 86:1534-1539.
11. Gulley ML, Nicholls JM, Schneider BG, Amin MB, Ro JY, and Geradts J (1998). Nasopharyngeal carcinomas frequently lack the p16/MTS1 tumor suppressor protein but express the retinoblastoma gene product. Am J Pathol 152:865-869.
12. Haber MM, Liu J, Knowles DM, and Inghirami G (1992). Determination of the DNA content of the Reed-Sternberg cell of Hodgkin's disease by image analysis. Blood 80:2851-2857.
13. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, and Warnke RA (1994). A revised European-American classification of lymphoid neoplasm: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392.
14. Herman JG, Graft JR, Myöhänen S, Nelkin BD, and Baylin SB (1996). Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93:9821-9826.
15. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, and Baylin SB (1995). Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525-4530.
16. Jansen MPHM, Hopman AHN, Haesevoets AM, Gennotte IAF, Bot FJ, Arends JW, Ramaekers FCS, and Schouten HC (1998). Chromosomal abnormalities in Hodgkin's disease are not restricted to Hodgkin/Reed-Sternberg cells. J Pathol 185:145-152.
17. Kanzler H, Kuppers R, Hansmann ML, and Rajewsky K (1996). Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 184:1495-1505.
18. Klangby U, Okan I, Magnusson KP, Wendland M, Lind P, and Wilman KG (1998). p16/INK4A and p15/INK4B gene methylation and absence of p16/INK4A mRNA and protein expression in Burkitt's lymphoma. Blood 91:1680-1687.
19. Koduru PR, Zariwala M, Soni M, Gong JZ, Xiong Y, and Broome JD (1995). Deletion of cyclin-dependent kinase 4-inhibitor genes p15 and p16 in non-Hodgkin's lymphoma. Blood 86:2900-2905.
20. Kratzke RA, Greatens TM, Rubins JB, Maddaus MA, Niewoehner DE, Niehans GA, and Geradts J (1996). Rb and p16/INK4a expression in resected non-small cell lung tumors. Cancer Res 56:3415-3420.
21. Mao L, Merlo A, Bedi G, Shapiro Gl, Edwards CD, Rollins BJ, and Sidransky D (1995). A novel p16/INK4A transcript. Cancer Res 55:2995-2997.
22. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, and Sidransky D (1995). 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1:686-692.
23. Morente MM, Piris MA, Abraira V, Acevedo A, Aguilera B, Bellas C, Fraga M, García-Del-Moral R, Gómez-Marcos F, Menárguez J, Oliva H, Sánchez-Beato M, and Montalbán C (1997). Adverse clinical outcome in Hodgkin's disease is associated with loss of Retinoblastoma protein expression, high ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression. Blood 90:2426-2436.
24. Ogawa S, Hangaishi A, Miyawaki S, Hirosawa S, Miura Y, Takeyama K, Kamada N, Ohtake S, Uike N, and Shimazaki C (1995). Loss of the cyclin-dependent kinase 4-inhibitor (p16: MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood 86:1548-1556.
25. Otsuki T, Clark HM, Wellmann A, Jaffe ES, and Raffeld M (1995). Involvement of CDKN2 (p16INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas. Cancer Res 55:1436-1440.
26. Peter M and Herskowitz I (1994). Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 79:181-184.
27. Pinyol M, Cobo F, Bea S, Jares P, Nayach I, Fernández PL, Montserrat E, Cardesa A, and Campo E (1998). p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 91:2977-2984.
28. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Swell D, Nawroz H, Bartek J, and Sidransky D (1996). High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 56:3630-3633.
29. Rigal-Huguet F, Gopas J, Prinsloo I, Pris J, Delsol G, Reed JC, Schlaifer D, Brousset P, Benharroch D, Krajewski S, Laurent G, and Meggetto F (1996). Frequent expression of the cell death-inducing gene Bax in Reed-Sternberg cells of Hodgkin's disease. Blood 87:2470-2475.
30. Russo AA, Tong L, Lee J, Jeffrey PD, and Pavletich NP (1998). Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumor suppressor p16INK4a. Nature 395:237-243.
31. Sánchez-Beato M, Martínez-Montero JC, Doussis-Anagnostopoulou TA, Gatter KC, García J, García JF, LLoret E, and Piris MA. (1996a). Anomalous retinoblastoma protein expression in Sternberg-Reed cells in Hodgkin's disease: A comparative study with p53 and Ki67 expression. Br J Cancer 74:1056-1062.
32. Sénchez-Beato M, Piris MA, Martínez-Montero JC, García JF, Villuendas R, Garcia FJ, Orradre JL, and Martinez P. (1996b). MDM2 and p21/WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease. J Pathol 180:58-64.
33. Sherr CJ and Roberts JM (1995). Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149-1163.
34. Tilly H, Bastard C, Delastre T, Duval C, Bizet M, Lenormand B, Daucé JP, Monconduit M, and Piguet H (1991). Cytogenetic studies in untreated Hodgkin's disease. Blood 77: 1298-1304.
35. Uchida T, Watanabe T, Kinoshita T, Murate T, Saito H, and Hotta T (1995). Mutational analysis of the CDKN2 (MTS1/p16ink4A) gene in primary B-cell lymphomas. Blood 86: 2724-2731.
36. Villuendas R, Sánchez-Beato M, Martínez JC, Sáez AI, Martínez-Delgado B, García JF, Mateo MS, Sánchez-Verde L, Benítez J, Martínez P, and Piris MA (1998). Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. Am J Pathol 153:887-897.
37. Wong DJ, Barrett MT, Stöger R, Emond MJ, and Reid BJ (1997). p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res 57: 2619-2622.